SNYR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient investor. The tape is weak/indecisive (price below pivot with no strong momentum signals), near-term pattern-based odds lean negative over the next week/month, and the latest quarter shows profit/EPS deterioration despite revenue growth. With no clear catalyst and no proprietary buy signals today, this is better as a watch/hold rather than an immediate entry.
Trend/momentum is mixed-to-soft. Current price is 1.87 (down -2.17% regular session) and sits below the pivot at 1.91, implying sellers still have control unless it reclaims that level. RSI(6) ~50.95 is neutral (no edge). MACD histogram is slightly positive (0.0102) but contracting, suggesting bullish momentum is fading rather than strengthening. Moving averages are converging, which often precedes a breakout but provides no direction by itself. Key levels: support S1 1.74 (then S2 1.634); resistance R1 2.08 (then R2 2.185). The provided pattern-based projection also leans bearish: ~-3.52% next week and ~-5.39% next month, which argues against chasing now.
Intellectia Proprietary Trading Signals
Analyst remains constructive: Roth Capital keeps a Buy rating and notes improved distribution footprint and geographic expansion; also highlights that the company now has capital from a recent equity raise to support growth in
Revenue is growing (Q3 2025 up 12.40% YoY) and gross margin improved to 70.5% (+5.62% YoY), which can support future earnings if operating costs stabilize.
Clear upside to the (reduced) analyst target: $7 vs. current ~$1.87 (high implied upside, albeit speculative).
Profitability deterioration: Q3 2025 net income down -84.01% YoY and EPS down -90% YoY, which typically pressures micro/small-cap sentiment.
No near-term news catalysts (no news in the recent week) to force a momentum reversal.
Technical posture is not supportive for an immediate buy: price below pivot (1.
and momentum is not accelerating; near-term statistical/pattern outlook points to further weakness over 1 week/1 month.
Hedge funds/insiders show neutral activity (no supporting accumulation signal).
Recent equity raise (noted by analyst) can be interpreted as dilution risk even if it improves liquidity.
Latest quarter: 2025/Q3. Revenue increased to 8,010,112 (+12.40% YoY), showing top-line growth and improved gross margin (70.5%, +5.62% YoY). However, net income fell to 125,327 (-84.01% YoY) and EPS to 0.01 (-90.00% YoY), indicating that higher sales are not translating into earnings—this is a meaningful negative trend for near-term buyers.
Most recent analyst update (2025-11-14): Roth Capital (Sean McGowan) lowered the price target to $7 from $10 while reiterating a Buy. Pros (Wall St. view): sees distribution/geographic expansion progress and believes fresh capital positions the company for significant 2026 growth. Cons: results missed expectations and cash constraints were a recent headwind (even if improved post-raise). Overall, the rating is positive, but the target cut reflects tempered near-term confidence.
Politicians/Congress trading: No recent congress trading data available in the last 90 days.
